NY-IFF
15.4.2021 22:17:49 CEST | Business Wire | Press release
IFF (NYSE: IFF) today introduced a new “Learning Labs” video series, featuring in-depth discussions with the leadership of the company’s segments and R&D function. Each video provides a comprehensive overview of IFF’s robust portfolio and enhanced capabilities following its recently completed merger with DuPont’s Nutrition and Biosciences (“N&B”) business. The complete “Learning Labs” series can be found here: ir.iff.com/events-presentations . In addition, IFF has also provided segment-level financial detail based on 2020 pro forma results.
“As a global industry leader of high-value consumer ingredients, we are pleased to provide a closer look into our capabilities, operational model and future growth potential,” said Andreas Fibig, IFF Chairman and CEO. “Stakeholder communication remains essential to IFF’s continued growth, and since combining with N&B, we have continued to explore new ways to meaningfully connect with our investors. The insights shared through our ‘Learning Labs’ series and detail provided in our 2020 pro forma segment financials is a testament to our commitment to continued transparency and greater comparability to peers.”
IFF 2020 Pro Forma Segment-Level Financial Results
To accompany the “Learning Labs” video series, IFF has provided additional detail on the financial performance, including sales and adjusted EBITDA metrics, for each of the company’s four segments on a 2020 pro forma basis.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
International Flavors & Fragrances Inc. |
|||||||||||
2020 Pro Forma Combined Reporting Segments (1)(2) |
|||||||||||
(Dollars in millions) |
|||||||||||
|
Q1
|
|
Q2
|
|
Q3
|
|
Q4
|
|
Pro Forma
|
|
Pro Forma
|
|
|
|
|
|
|
|
|
|
|
|
|
Nourish Pro Forma Sales |
1,276 |
|
1,450 |
|
1,418 |
|
1,488 |
|
5,632 |
|
5,887 |
Nourish Pro Forma Adjusted Operating EBITDA |
255 |
|
303 |
|
275 |
|
257 |
|
1,090 |
|
1,153 |
as % of Pro Forma Sales |
20% |
|
21% |
|
19% |
|
17% |
|
19% |
|
20% |
|
|
|
|
|
|
|
|
|
|
|
|
Scent Pro Forma Sales |
541 |
|
475 |
|
525 |
|
524 |
|
2,064 |
|
2,064 |
Scent Pro Forma Adjusted Operating EBITDA |
118 |
|
87 |
|
118 |
|
93 |
|
416 |
|
416 |
as % of Pro Forma Sales |
22% |
|
18% |
|
22% |
|
18% |
|
20% |
|
20% |
|
|
|
|
|
|
|
|
|
|
|
|
Health & Biosciences Pro Forma Sales |
427 |
|
588 |
|
579 |
|
572 |
|
2,166 |
|
2,353 |
Health & Biosciences Pro Forma Adjusted Operating EBITDA |
131 |
|
181 |
|
172 |
|
149 |
|
634 |
|
680 |
as % of Pro Forma Sales |
31% |
|
31% |
|
30% |
|
26% |
|
29% |
|
29% |
|
|
|
|
|
|
|
|
|
|
|
|
Pharma Solutions Pro Forma Sales |
152 |
|
224 |
|
215 |
|
188 |
|
779 |
|
839 |
Pharma Solutions Pro Forma Adjusted Operating EBITDA |
42 |
|
62 |
|
61 |
|
38 |
|
203 |
|
216 |
as % of Pro Forma Sales |
28% |
|
28% |
|
28% |
|
20% |
|
26% |
|
26% |
|
|
% Change in Sales - 2020 vs. 2019 (5) |
||||||||||
|
|
Q1 (3) |
|
Q2 |
|
Q3 |
|
Q4 |
||||
|
|
Reported |
Currency
|
|
Reported |
Currency
|
|
Reported |
Currency
|
|
Reported |
Currency
|
Nourish |
|
3% |
5% |
|
(4)% |
(1)% |
|
(5)% |
(3)% |
|
—% |
1% |
Scent |
|
4% |
7% |
|
(6)% |
—% |
|
4% |
9% |
|
4% |
6% |
Health & Biosciences |
|
8% |
11% |
|
(4)% |
(2)% |
|
(1)% |
—% |
|
1% |
—% |
Pharma Solutions |
|
9% |
11% |
|
6% |
7% |
|
2% |
1% |
|
(2)% |
(4)% |
Total |
|
4% |
7% |
|
(4)% |
—% |
|
(2)% |
—% |
|
1% |
1% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro Forma FY 2020
|
|
Pro Forma FY 2020 (4) |
|
|
|
|
|
|
||
|
|
Reported |
Currency
|
|
Reported |
Currency
|
|
|
|
|
|
|
Nourish |
|
(2)% |
—% |
|
(2)% |
—% |
|
|
|
|
|
|
Scent |
|
2% |
5% |
|
2% |
5% |
|
|
|
|
|
|
Health & Biosciences |
|
—% |
1% |
|
—% |
1% |
|
|
|
|
|
|
Pharma Solutions |
|
4% |
3% |
|
1% |
1% |
|
|
|
|
|
|
Total |
|
—% |
2% |
|
(1)% |
1% |
|
|
|
|
|
|
_______________________
Note: Adjusted Operating EBITDA for each segment is defined as Income (Loss) Before Taxes before depreciation and amortization expense, interest expense, restructuring and other charges, net and certain non-recurring items. Additionally, all corporate expenses have been allocated to all of the reportable segments.
- The pro forma historical segment information has been presented for informational purposes only and is not necessarily indicative of what IFF's results of operations actually would have been, had the N&B transaction occurred on the dates indicated below. In addition, the pro forma historical segment information does not purport to project the future operating results of the Company.
- Dollar amounts may not foot due to rounding.
- The first quarter and Pro Forma FY 2020 (excl. N&B Jan.) show the combination of the historical results of IFF and N&B as if the N&B transaction had been consummated on February 1, 2020. Therefore, the first quarter and Pro Forma FY 2020 (excl. N&B Jan.) do not include the N&B business for the month of January 2020, which would allow comparability against the 2021 calendar year since the merger occurred on February 1, 2021. Total N&B Sales and Adjusted Operating EBITDA included in reportable segments for the month of January 2020 amounted to $502 million and $124 million, respectively.
- Pro Forma FY 2020 shows the combination of the historical results of IFF and N&B as if the N&B Transaction had been consummated on January 1, 2020. Therefore, Pro Forma FY 2020 includes a full twelve months of 2020 N&B and IFF results.
- Effective 2021, we calculate currency neutral growth by translating current year invoiced sale amounts at the average exchange rates used for the corresponding prior year period. Previously we calculated currency neutral numbers by comparing current year results to the prior year results restated at exchange rates in effect for the current year based on the currency of the underlying transaction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210415006035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Group Reports Cybersecurity Incidents in Japan19.11.2026 05:39:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical Group" or the "Company"), a provider of comprehensive management services to medical corporations and their clinics, today reported the occurrence of recent cybersecurity incidents involving customer information associated with certain clinics in Japan, along with the status of its response. Overview of the Incidents On November 16, 2026, unauthorized access occurred to certain databases within a website system managed and operated by SBC Medical Group, Ltd., the Company’s, Japanese subsidiary, in connection with its management services in Japan. The Company confirmed that an unauthorized third party accessed and extracted customer information. The method of intrusion and full scope remain under investigation. Based on current information, the information obtained and the number of affected customers are as follows: Category Types of information Individuals Period Basic personal information (without reservation or trea
Lenovo Group: Q2 Financial Results 2026/2719.11.2026 05:20:00 CET | Press release
Lenovo delivers record Q2 performance, confident in long-term Hybrid AI opportunities Lenovo GroupLimited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today reported second quarter results for fiscal year 2026/27, demonstrating strong growth, a leap forward in profitability, and structural enhancements to the Group’s business fundamentals. Overall Group revenue for the second quarter reached an all-time high of US$30.2 billion, up 48% year-on-year. All business groups delivered record second-fiscal-quarter revenue while demonstrating strong profitability, with the Infrastructure Solutions Group (ISG) becoming an engine of hyper-growth with operating profit surpassing US$1 billion for the first time. Adjusted net income[1]was up 166% year-on-year to US$1.4 billion, with adjusted net margin improvements of two percentage points year-on-year. AI-related revenue[2] grew 79% year-on-year, surpassing the US$10 billion mark for the first time and accounting for 36%
WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel18.11.2026 18:00:00 CET | Press release
Four-year global partnership makes WHOOP an Official Partner of Formula 1 bringing physiological insights into the broadcast beginning in 2027 WHOOP, the human performance brand, today announced a four-year global partnership with Formula 1, becoming the Official Health & Fitness Wearable Partner of Formula 1 and the first consumer wearable approved by the FIA for in-race use. Beginning in 2027, the partnership will bring continuous physiological monitoring to one of the world's most demanding sports, helping drivers and teams better understand how their bodies respond to the demands of competition while giving fans a new perspective on the human performance behind the wheel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118567291/en/ WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel WHOOP is working to bring fans closer to the action than ever before, with Formula 1 integrating real-time physi
Future Health Launches Academy to Translate Life Sciences Advances Into Strategic Action18.11.2026 15:37:00 CET | Press release
Future Health Academy will build knowledge and connect expertise among health and life sciences professionals in Abu Dhabi and internationally. The Academy will support two-way knowledge exchange, bringing global expertise to Abu Dhabi while creating opportunities to share Abu Dhabi’s knowledge, expertise and innovation with the world. Inaugural course brought together senior leaders from government, healthcare, research, and industry with local and international scientific experts. Future Health - A Global Initiative by Abu Dhabi has launched the Future Health Academy as part of its year-round programme, designed to build knowledge, connect expertise and create opportunities for collaboration among health and life sciences professionals in Abu Dhabi and internationally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118051527/en/ The Future Health Academy will build knowledge and connect expertise among health and life s
Soracom Launches Physical AI Suite, Bringing Secure Connectivity and Remote Operations to Robots and Autonomous Machines18.11.2026 15:30:00 CET | Press release
Soracom suite combines existing platform services for physical AI, available worldwide Soracom, Inc. (TSE: 147A), a cloud-native IoT platform providing connectivity, cloud integration, and AI services for the Internet of Things, today announced Soracom Physical AI Suite, a set of Soracom platform services combined to connect, protect, and manage physical AI systems such as robots, autonomous mobile machines, and industrial equipment. Soracom Physical AI Suite is the company's second suite, following Soracom Automotive Suite announced in July 2026. Each suite brings together Soracom platform services commonly used for a particular type of deployment, organizing them into a single system. A team starting a new deployment begins from that system instead of selecting and assembling services one at a time. The suite is designed for companies that develop or deploy robots and other physical AI systems and for companies that operate connected equipment in industries including manufacturing, l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
